Bio-Techne (TECH) 10-Q 7 Nov 18 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2018	Nov. 02, 2018
Document Information [Line Items]
Entity Registrant Name	BIO-TECHNE Corp
Entity Central Index Key	842,023
Trading Symbol	tech
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		37,765,765
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Net sales	$ 162,970	$ 144,613
Cost of sales	55,367	46,745
Gross margin	107,603	97,868
Operating expenses:
Selling, general and administrative	67,051	58,289
Research and development	14,789	13,548
Total operating expenses	81,840	71,837
Operating income	25,763	26,031
Other (expense) income	(8,177)	(3,064)
Earnings before income taxes	17,586	22,967
Income taxes	183	7,104
Net earnings	17,403	15,863
Other comprehensive (loss) income:
Foreign currency translation adjustments	(1,136)	6,968
Unrealized gains and losses on available-for-sale investments		(7,792)
Other comprehensive (loss) income	(1,136)	(824)
Comprehensive income	$ 16,267	$ 15,039
Earnings per share:
Basic (in dollars per share)	$ 0.46	$ 0.42
Diluted (in dollars per share)	0.45	0.42
Cash dividends per common share: (in dollars per share)	$ 0.32	$ 0.32
Weighted average common shares outstanding:
Basic (in shares)	37,697	37,376
Diluted (in shares)	38,813	37,705

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
ASSETS
Cash and cash equivalents	$ 94,674	$ 121,990
Short-term available-for-sale investments	69,047	59,764
Accounts receivable, less allowance for doubtful accounts of $1,007 and $839, respectively	114,753	120,296
Inventories	90,918	85,648
Other current assets	13,720	10,668
Total current assets	383,112	398,366
Property and equipment, net	146,511	145,348
Goodwill	704,790	597,890
Intangible assets, net	632,686	446,332
Other assets	5,099	5,266
Total assets	1,872,198	1,593,202
LIABILITIES AND SHAREHOLDERS' EQUITY
Trade accounts payable	18,259	18,452
Salaries, wages and related accruals	15,180	23,710
Accrued expenses	23,509	20,361
Contract liabilities	8,762	8,109
Income taxes payable	5,232	8,878
Current portion of long-term debt obligations	12,500
Total current liabilities	83,442	79,510
Deferred income taxes	113,843	86,293
Long-term debt obligations, net of deferred financing costs of $402 and $0, respectively	548,973	339,000
Long-term contingent consideration payable	6,800
Other long-term liabilities	9,671	9,338
Shareholders' equity:
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 37,802,998 and 37,607,500, respectively	378	376
Additional paid-in capital	274,584	246,568
Retained earnings	905,139	876,931
Accumulated other comprehensive loss	(70,632)	(44,814)
Total shareholders' equity	1,109,469	1,079,061
Total liabilities and shareholders’ equity	$ 1,872,198	$ 1,593,202

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Accounts receivable, allowance for doubtful accounts	$ 1,007	$ 839
Deferred financing costs	$ 402	$ 0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	37,802,998	37,607,500
Common stock, shares outstanding (in shares)	37,802,998	37,607,500

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	$ 17,403	$ 15,863
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	19,052	15,423
Costs recognized on sale of acquired inventory	935	318
Deferred income taxes	(3,768)	(2,184)
Stock-based compensation expense	11,565	3,795
Fair value adjustment to contingent consideration payable	(200)	7,500
Fair value adjustment on available for sale investments	2,202
Other operating activity	2,217	277
Change in operating assets and operating liabilities, net of acquisition:
Trade accounts and other receivables, net	8,307	9,550
Inventories	(6,678)	(5,446)
Other current assets	(1,354)	48
Trade accounts payable, accrued expenses, and contract liabilities	3,107	(563)
Salaries, wages and related accruals	(8,476)	(3,635)
Income taxes payable	(4,864)	3,750
Net cash provided by operating activities	39,448	44,696
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from maturities of available-for-sale investments		3,502
Purchases of available-for-sale investments	(11,694)
Additions to property and equipment	(4,190)	(5,273)
Acquisitions, net of cash acquired	(272,229)	(10,634)
Net cash used in investing activities	(288,113)	(12,405)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash dividends	(12,066)	(11,958)
Proceeds from stock option exercises	16,453	3,806
Proceeds from long-term debt	580,000
Repayments of long-term debt	(357,125)	(6,000)
Payments of contingent consideration		(35,000)
Debt issuance costs	(3,004)
Other financing activity	(1,727)	(1,802)
Net cash provided by (used in) financing activities	222,531	(50,954)
Effect of exchange rate changes on cash and cash equivalents	(1,182)	(485)
Net decrease in cash and cash equivalents	(27,316)	(19,148)
Cash and cash equivalents at beginning of period	121,990	91,612
Cash and cash equivalents at end of period	94,674	72,464
Supplemental disclosure of cash flow information:
Cash paid for income taxes	8,447	6,071
Cash paid for interest	$ 3,229	$ 2,144

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. The interim consolidated financial statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10 10 X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2018, 10 2018. 10 2018. Effective in the first 2019, not 2019. five two ● “Diagnostics and Genomics” will consist of the ACD operating segment, the Diagnostics operating segment, and the ExosomeDx operating segment. As part of the realignment, ACD will now be referred to as the Genomics operating segment. ● “Protein Sciences” will consist of the Core Biotechnology operating segment and the Protein Platforms operating segment. As part of the realignment, Protein Platforms will now be referred to as the Analytical Solutions Division (ASD) operating segment and Core Biotechnology will now be referred to as the Reagent Solutions Division (RSD) operating segment. Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, 606 On July 1, 2018, 606 July 1, 2018 606, not 605, Revenue Recognition The Company recorded a net increase to beginning retained earnings of $98,000 July 1, 2018 606. 606 not three September 30, 2018 not 2 606. In January 2016, No. 2016 01 Recognition and Measurement of Financial Assets and Financial Liabilities no 2016 01 July 1, 2018 $54.3 $35.4 $8.3 $27.1 2019. 2016 01, July 1, 2018 $2.2 three September 30, 2018 2016 01 In February 2018, No. 2018 02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income 2017. December 15, 2018, July 1, 2019. 2018 02 July 1, 2018. As a result of adopting this standard, we recorded a cumulative effect adjustment to increase AOCI by $2.4 2018 02 2016 01 The following table presents a summary of cumulative effect adjustments to retained earnings due to the adoption of new accounting standards on July 1, 2018 Cumulative Effect Adjustments to Retained Earnings on July 1, 2018 Increase / (Decrease) Cumulative effect adjustment to retained earnings due to the adoption of the following new accounting standards: ASU 2014-09 $ 98 ASU 2016-01 27,053 ASU 2018-02 (2,371 ) Net cumulative effect adjustments to retained earnings on July 1, 2018 due to the adoption of new accounting standards $ 24,780 In January 2017, No. 2017 01, Clarifying the Definition of a Business July 1, 2018, Pronouncements Issued But Not In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, July 1, 2019. July 2018, No. 2018 10, Codification Improvements to Topic 842, Leases No. 2016 02. not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not December 15, 2019, July 1, 2020 may first 2018 15

Note 2 - Revenue Recognition

Note 2 - Revenue Recognition	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	N ote 2. : Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects that are recognized over time as customers receive and consume the benefits of such services. Royalty revenues are based on net sales of the Company’s licensed products by a third third Contracts with customers that contain instruments may Payment terms for shipments to end-users are generally net 30 may 30 90 Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one one September 30, 2018 not Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of the adoption date and subsequently recognized as revenue during the first 2019 $3.8 September 30, 2018 $10.6 Any claims for credit or return of goods must be made within 10 not Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented. Revenue by type is as follows: Quarter Ended September 30, 2018 2017 Consumables $ 135,653 $ 120,102 Instruments 15,346 12,988 Services 8,301 8,378 Total product and services revenue, net $ 159,299 $ 141,766 Royalty revenues 3,671 2,847 Total revenues, net $ 162,970 $ 144,613 Revenue by geography is as follows: Quarter Ended September 30, 2018 2017 United States $ 90,455 $ 79,819 EMEA, excluding United Kingdom 35,233 31,390 United Kingdom 7,128 6,924 APAC, excluding Greater China 11,629 11,489 Greater China 13,422 10,717 Rest of World 5,103 4,274 Total revenues, net $ 162,970 $ 144,613

Note 3 - Selected Balance Sheet

Note 3 - Selected Balance Sheet Data	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	N ote 3 . Selected Balance Sheet Data : Inventories: Inventories consist of (in thousands): September 30, June 30, 2018 2018 Raw materials $ 32,082 $ 30,956 Finished goods 58,836 54,692 Inventories, net $ 90,918 $ 85,648 Property and Equipment: Property and equipment consist of (in thousands): September 30, June 30, 2018 2018 Land $ 7,065 $ 7,065 Buildings and improvements 171,580 170,110 Machinery and equipment 115,769 107,625 Property and equipment, cost 294,414 284,800 Accumulated depreciation and amortization (147,903 ) (139,452 ) Property and equipment, net $ 146,511 $ 145,348 Intangible Assets: Intangible assets consist of (in thousands): September 30, June 30, 2018 2018 Developed technology $ 505,131 $ 305,303 Trade names 89,567 89,608 Customer relationships 212,702 212,228 Patents 1,707 1,401 Intangible assets 809,107 608,540 Accumulated amortization (176,421 ) (162,208 ) Intangible assets, net $ 632,686 $ 446,332 Changes to the carrying amount of net intangible assets for the quarter ended September 30, 2018 Beginning balance $ 446,332 Acquisitions 200,000 Other additions 285 Amortization expense (14,313 ) Currency translation 382 Ending balance $ 632,686 The estimated future amortization expense for intangible assets as of September 30, 2018 2019 remainder $ 45,850 2020 60,475 2021 60,120 2022 58,424 2023 56,549 Thereafter 351,268 Total $ 632,686 Goodwill: Changes to the carrying amount of goodwill for the quarter ended September 30, 2018 Protein Sciences Diagnostics and Genomics Total Beginning balance $ 347,918 249,972 $ 597,890 Acquisitions (Note 4) 9,790 96,592 106,382 Currency translation 537 (19 ) 518 Ending balance $ 358,245 $ 346,545 $ 704,790 We evaluate the carrying value of goodwill in the fourth fourth 2018. June 30, 2018. No September 30, 2018. no 350 July 1, 2002.

Note 4 - Acquisitions

Note 4 - Acquisitions	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 4 . Acquisitions: We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and the results of operations of each acquired business are included in our consolidated statements of comprehensive income from their respective dates of acquisition. Acquisition costs are recorded in selling, general and administrative expenses as incurred. Quad Technologies On July 2, 2018, $20.4 $51.0 not first 2019. Certain estimated fair values are not fourth 2019 Preliminary Allocation at Acquisition Date Current assets, net of cash $ 36 Equipment and other long-term assets 284 Intangible assets: Developed technology 20,000 Goodwill 9,790 Total assets acquired 30,110 Liabilities 765 Deferred income taxes, net 3,741 Net assets acquired $ 25,604 Cash paid, net of cash acquired $ 20,404 Fair value of contingent consideration 5,200 Net assets acquired $ 25,604 Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The preliminary amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The preliminary amortization periods for intangible assets acquired in fiscal 2019 15 not Exosome Diagnostics On August 1, 2018, $251.8 $325.0 ● Up to $250 2020 $45 $58 ● Up to $45 2022 $54 $70 ● Up to $30 2022 $150 $190 The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not first 2019. Certain estimated fair values are not fourth 2019 Preliminary Allocation at Acquisition Date Current assets, net of cash $ 5,118 Equipment and other long-term assets 2,212 Intangible assets: Developed technology 180,000 Goodwill 96,592 Total assets acquired 283,922 Liabilities 2,624 Deferred income taxes, net 27,673 Net assets acquired $ 253,625 Cash paid, net of cash acquired $ 251,825 Fair value of contingent consideration 1,800 Net assets acquired $ 253,625 Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The preliminary amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The preliminary amortization periods for intangible assets acquired in fiscal 2019 15 not

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Note 5 . Fair Value Measurements: The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three 1 2 not 3 one 3 may The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): Total carrying value a s of Fair Value Measurements Using Inputs Considered as September 30, 2018 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 52,084 $ 52,084 $ - $ - Certificates of Deposit (2) 16,963 16,963 - - Total Assets $ 69,047 $ 69,047 $ - $ - Liabilities Contingent Consideration $ 6,800 $ - $ - $ 6,800 Total carrying value a s of Fair Value Measurements Using Inputs Considered as June 30, 201 8 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 54,286 $ 54,286 $ - $ - Certificates of Deposit (2) 5,478 5,478 - - Total Assets $ 59,764 $ 59,764 $ - $ - Liabilities Contingent Consideration $ - $ - $ - $ - ( 1 Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at September 30, 2018 June 30, 2018 $18.8 ( 2 Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one Our available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 In connection with the ExosomeDx and Quad acquisitions the Company is required to make contingent consideration payments of up to $325.0 $51.0 $7.0 $1.8 $5.2 3 The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 September 30, 2018 ( Quarter Ended September 30, 2018 Fair value at the beginning of period $ - Purchase price contingent consideration (Note 4) 7,000 Change in fair value of contingent consideration (200 ) Payments - Fair value at the end of period $ 6,800 The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we may may Fair value measurements of other financial instruments Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items. Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility approximates fair value because our interest rate is variable and reflects current market rates.

Note 6 - Debt and Other Financi

Note 6 - Debt and Other Financing Arrangements	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 6 . Debt and Other Financing Arrangements: On August 1, 2018, $600.0 $200.0 $250.0 may 20 The Credit Agreement matures on August 1, 2023 August 1, 2018, $250.0 $330.0 September 30, 2018, $561.9

Note 7 - Accumulated Other Comp

Note 7 - Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	Note 7 . Accumulated Other Comprehensive Income (Loss) : The components of other comprehensive income (loss) consist of changes in net unrealized gains (losses) on available for sale investments with readily determinable fair values in 2017 no three September 30, 2018 2017. The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows: Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Total Balance as of June 30, 2018 $ 24,682 $ (69,496 ) $ (44,814 ) Cumulative effect adjustment for adoption for ASU 2018-02 (1) 2,371 2,371 Cumulative effect adjustment for adoption of ASU 2016-01 (1) (27,053 ) (27,053 ) Other comprehensive income (loss), net of tax before reclassifications - (1,136 ) (1,136 ) Balance as of September 30, 2018 $ - $ (70,632 ) $ (70,632 ) ( 1 1 2016 01 2018 02. Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Total Balance as of June 30, 2017 $ 18,989 $ (67,924 ) $ (48,935 ) Other comprehensive income (loss), net of tax benefit of $4,576 before reclassifications (7,792 ) 6,968 (824 ) Balance as of September 30, 2017 $ 11,197 $ (60,956 ) $ (49,759 )

Note 8 - Earnings Per Share

Note 8 - Earnings Per Share	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 8 . Earnings Per Share: The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): Quarter Ended September 30, 201 8 201 7 Earnings per share – basic: Net Income $ 17,403 $ 15,863 Income allocated to participating securities (16 ) (10 ) Income available to common shareholders $ 17,387 $ 15,853 Weighted-average shares outstanding 37,697 37,376 Earnings per share-basic $ 0.46 $ 0.42 Earnings per share – diluted: Net Income $ 17,403 $ 15,863 Income allocated to participating securities (16 ) (10 ) Income available to common shareholders $ 17,387 $ 15,853 Weighted average common shares outstanding-basic 37,697 37,376 Dilutive effect of stock options and restricted stock units 1,116 329 Weighted average common shares outstanding-diluted 38,813 37,705 Earnings per share-diluted $ 0.45 $ 0.42 The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation for the first 2019 2018 1.3

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 9. During the quarter ended September 30, 2018 2017, 0.9 0.6 $173.33 $114.60 $34.30 $20.47, September 30, 2018 2017, 53,903 500 $170.74 $122.57, September 30, 2018, 11,279 $177.32. not September 30, 2017. Stock options for 166,577 32,625 $14.9 $0.9 September 30, 2018 2017, Stock-based compensation expense of $11.6 $3.8 September 30, 2018 2017, September 30, 2018, $42.7 2.4

Note 10 - Other Income (Expense

Note 10 - Other Income (Expense)	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	Note 10 . Other Income / (Expense): The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows: Quarter Ended September 30, 2018 2017 Interest expense $ (5,239 ) $ (2,243 ) Interest income 102 76 Other non-operating income (expense), net (3,040 ) (897 ) Total other income (expense) $ (8,177 ) $ (3,064 )

Note 11 - Income Taxes

Note 11 - Income Taxes	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 1 1 . Income Taxes: The Company’s effective income tax rate for the first 2019 2018 1.0% 30.9% first 2019 first 2018 $4.2 first 2019 $0.4 first 2018. On December 22, 2017, 35% 21%, one 118” 2018 05 Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin (SAB) No. 118 one We complied with SAB No. 118 September 30, 2018. 2018 1986 No September 30, 2018 2018. not

Note 12 - Segment Information

Note 12 - Segment Information	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 12. The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Genomics reportable segments both include consumables, instruments, services and royalty revenue. The following is financial information relating to the Company's reportable segments (in thousands): Quarter Ended September 30, 2018 2017 Net sales: Protein Sciences $ 126,391 $ 108,113 Diagnostics and Genomics 36,747 36,589 Intersegment (168 ) (89 ) Consolidated net sales $ 162,970 $ 144,613 Operating income: Protein Sciences $ 54,614 $ 46,209 Diagnostics and Genomics 2,536 7,279 Segment operating income 57,150 53,488 Costs recognized on sale of acquired inventory (935 ) (318 ) Amortization of acquisition related intangible assets (14,276 ) (11,379 ) Acquisition related expenses (2,631 ) (9,533 ) Stock-based compensation (11,565 ) (3,795 ) Corporate general, selling, and administrative expenses (1,980 ) (2,432 ) Consolidated operating income $ 25,763 $ 26,031

Note 13 - Subsequent Events

Note 13 - Subsequent Events	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	Note 13. In October 2018, $380

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, 606 On July 1, 2018, 606 July 1, 2018 606, not 605, Revenue Recognition The Company recorded a net increase to beginning retained earnings of $98,000 July 1, 2018 606. 606 not three September 30, 2018 not 2 606. In January 2016, No. 2016 01 Recognition and Measurement of Financial Assets and Financial Liabilities no 2016 01 July 1, 2018 $54.3 $35.4 $8.3 $27.1 2019. 2016 01, July 1, 2018 $2.2 three September 30, 2018 2016 01 In February 2018, No. 2018 02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income 2017. December 15, 2018, July 1, 2019. 2018 02 July 1, 2018. As a result of adopting this standard, we recorded a cumulative effect adjustment to increase AOCI by $2.4 2018 02 2016 01 The following table presents a summary of cumulative effect adjustments to retained earnings due to the adoption of new accounting standards on July 1, 2018 Cumulative Effect Adjustments to Retained Earnings on July 1, 2018 Increase / (Decrease) Cumulative effect adjustment to retained earnings due to the adoption of the following new accounting standards: ASU 2014-09 $ 98 ASU 2016-01 27,053 ASU 2018-02 (2,371 ) Net cumulative effect adjustments to retained earnings on July 1, 2018 due to the adoption of new accounting standards $ 24,780 In January 2017, No. 2017 01, Clarifying the Definition of a Business July 1, 2018, Pronouncements Issued But Not In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, July 1, 2019. July 2018, No. 2018 10, Codification Improvements to Topic 842, Leases No. 2016 02. not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not December 15, 2019, July 1, 2020 may first 2018 15

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Cumulative Effect Adjustments to Retained Earnings on July 1, 2018 Increase / (Decrease) Cumulative effect adjustment to retained earnings due to the adoption of the following new accounting standards: ASU 2014-09 $ 98 ASU 2016-01 27,053 ASU 2018-02 (2,371 ) Net cumulative effect adjustments to retained earnings on July 1, 2018 due to the adoption of new accounting standards $ 24,780

Note 2 - Revenue Recognition (T

Note 2 - Revenue Recognition (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Quarter Ended September 30, 2018 2017 Consumables $ 135,653 $ 120,102 Instruments 15,346 12,988 Services 8,301 8,378 Total product and services revenue, net $ 159,299 $ 141,766 Royalty revenues 3,671 2,847 Total revenues, net $ 162,970 $ 144,613 Quarter Ended September 30, 2018 2017 United States $ 90,455 $ 79,819 EMEA, excluding United Kingdom 35,233 31,390 United Kingdom 7,128 6,924 APAC, excluding Greater China 11,629 11,489 Greater China 13,422 10,717 Rest of World 5,103 4,274 Total revenues, net $ 162,970 $ 144,613

Note 3 - Selected Balance She_2

Note 3 - Selected Balance Sheet Data (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, June 30, 2018 2018 Raw materials $ 32,082 $ 30,956 Finished goods 58,836 54,692 Inventories, net $ 90,918 $ 85,648
Property, Plant and Equipment [Table Text Block]	September 30, June 30, 2018 2018 Land $ 7,065 $ 7,065 Buildings and improvements 171,580 170,110 Machinery and equipment 115,769 107,625 Property and equipment, cost 294,414 284,800 Accumulated depreciation and amortization (147,903 ) (139,452 ) Property and equipment, net $ 146,511 $ 145,348
Schedule of Intangible Assets and Goodwill [Table Text Block]	September 30, June 30, 2018 2018 Developed technology $ 505,131 $ 305,303 Trade names 89,567 89,608 Customer relationships 212,702 212,228 Patents 1,707 1,401 Intangible assets 809,107 608,540 Accumulated amortization (176,421 ) (162,208 ) Intangible assets, net $ 632,686 $ 446,332
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Beginning balance $ 446,332 Acquisitions 200,000 Other additions 285 Amortization expense (14,313 ) Currency translation 382 Ending balance $ 632,686
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2019 remainder $ 45,850 2020 60,475 2021 60,120 2022 58,424 2023 56,549 Thereafter 351,268 Total $ 632,686
Schedule of Goodwill [Table Text Block]	Protein Sciences Diagnostics and Genomics Total Beginning balance $ 347,918 249,972 $ 597,890 Acquisitions (Note 4) 9,790 96,592 106,382 Currency translation 537 (19 ) 518 Ending balance $ 358,245 $ 346,545 $ 704,790

Note 4 - Acquisitions (Tables)

Note 4 - Acquisitions (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Preliminary Allocation at Acquisition Date Current assets, net of cash $ 36 Equipment and other long-term assets 284 Intangible assets: Developed technology 20,000 Goodwill 9,790 Total assets acquired 30,110 Liabilities 765 Deferred income taxes, net 3,741 Net assets acquired $ 25,604 Cash paid, net of cash acquired $ 20,404 Fair value of contingent consideration 5,200 Net assets acquired $ 25,604 Preliminary Allocation at Acquisition Date Current assets, net of cash $ 5,118 Equipment and other long-term assets 2,212 Intangible assets: Developed technology 180,000 Goodwill 96,592 Total assets acquired 283,922 Liabilities 2,624 Deferred income taxes, net 27,673 Net assets acquired $ 253,625 Cash paid, net of cash acquired $ 251,825 Fair value of contingent consideration 1,800 Net assets acquired $ 253,625

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total carrying value a s of Fair Value Measurements Using Inputs Considered as September 30, 2018 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 52,084 $ 52,084 $ - $ - Certificates of Deposit (2) 16,963 16,963 - - Total Assets $ 69,047 $ 69,047 $ - $ - Liabilities Contingent Consideration $ 6,800 $ - $ - $ 6,800 Total carrying value a s of Fair Value Measurements Using Inputs Considered as June 30, 201 8 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 54,286 $ 54,286 $ - $ - Certificates of Deposit (2) 5,478 5,478 - - Total Assets $ 59,764 $ 59,764 $ - $ - Liabilities Contingent Consideration $ - $ - $ - $ -
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Quarter Ended September 30, 2018 Fair value at the beginning of period $ - Purchase price contingent consideration (Note 4) 7,000 Change in fair value of contingent consideration (200 ) Payments - Fair value at the end of period $ 6,800

Note 7 - Accumulated Other Co_2

Note 7 - Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Total Balance as of June 30, 2018 $ 24,682 $ (69,496 ) $ (44,814 ) Cumulative effect adjustment for adoption for ASU 2018-02 (1) 2,371 2,371 Cumulative effect adjustment for adoption of ASU 2016-01 (1) (27,053 ) (27,053 ) Other comprehensive income (loss), net of tax before reclassifications - (1,136 ) (1,136 ) Balance as of September 30, 2018 $ - $ (70,632 ) $ (70,632 ) Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Total Balance as of June 30, 2017 $ 18,989 $ (67,924 ) $ (48,935 ) Other comprehensive income (loss), net of tax benefit of $4,576 before reclassifications (7,792 ) 6,968 (824 ) Balance as of September 30, 2017 $ 11,197 $ (60,956 ) $ (49,759 )

Note 8 - Earnings Per Share (Ta

Note 8 - Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarter Ended September 30, 201 8 201 7 Earnings per share – basic: Net Income $ 17,403 $ 15,863 Income allocated to participating securities (16 ) (10 ) Income available to common shareholders $ 17,387 $ 15,853 Weighted-average shares outstanding 37,697 37,376 Earnings per share-basic $ 0.46 $ 0.42 Earnings per share – diluted: Net Income $ 17,403 $ 15,863 Income allocated to participating securities (16 ) (10 ) Income available to common shareholders $ 17,387 $ 15,853 Weighted average common shares outstanding-basic 37,697 37,376 Dilutive effect of stock options and restricted stock units 1,116 329 Weighted average common shares outstanding-diluted 38,813 37,705 Earnings per share-diluted $ 0.45 $ 0.42

Note 10 - Other Income (Expen_2

Note 10 - Other Income (Expense) (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Quarter Ended September 30, 2018 2017 Interest expense $ (5,239 ) $ (2,243 ) Interest income 102 76 Other non-operating income (expense), net (3,040 ) (897 ) Total other income (expense) $ (8,177 ) $ (3,064 )

Note 12 - Segment Information (

Note 12 - Segment Information (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Quarter Ended September 30, 2018 2017 Net sales: Protein Sciences $ 126,391 $ 108,113 Diagnostics and Genomics 36,747 36,589 Intersegment (168 ) (89 ) Consolidated net sales $ 162,970 $ 144,613 Operating income: Protein Sciences $ 54,614 $ 46,209 Diagnostics and Genomics 2,536 7,279 Segment operating income 57,150 53,488 Costs recognized on sale of acquired inventory (935 ) (318 ) Amortization of acquisition related intangible assets (14,276 ) (11,379 ) Acquisition related expenses (2,631 ) (9,533 ) Stock-based compensation (11,565 ) (3,795 ) Corporate general, selling, and administrative expenses (1,980 ) (2,432 ) Consolidated operating income $ 25,763 $ 26,031

Note 1 - Basis of Presentatio_3

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)	3 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Jul. 01, 2018USD ($)
Number of Operating Segments		5
Number of Reportable Segments	2
Retained Earnings (Accumulated Deficit), Ending Balance	$ 905,139,000	$ 876,931,000
Available-for-sale Securities, Total		54,300,000
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax, Total		35,400,000
Deferred Tax Liabilities, Other Comprehensive Income		8,300,000
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total	(70,632,000)	$ (44,814,000)
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance			$ 98,000
Accounting Standards Update 2016-01 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance			27,100,000
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total			(27,100,000)
Accounting Standards Update 2016-01 [Member] | Other Nonoperating Income (Expense) [Member]
Equity Securities, FV-NI, Gain (Loss), Total	$ (2,200,000)
Accounting Standards Update 2018-02 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance			(2,400,000)
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total			$ 1,900,000

Note 1 - Basis of Presentatio_4

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Cumulative Effect Adjustments to Retained Earnings (Details) - Retained Earnings [Member] $ in Thousands	Jul. 01, 2018USD ($)
Cumulative effect adjustment for adoption of ASU 2016-01 (1)	$ 24,780
Accounting Standards Update 2014-09 [Member]
Cumulative effect adjustment for adoption of ASU 2016-01 (1)	98
Accounting Standards Update 2016-01 [Member]
Cumulative effect adjustment for adoption of ASU 2016-01 (1)	27,053
Accounting Standards Update 2018-02 [Member]
Cumulative effect adjustment for adoption of ASU 2016-01 (1)	$ (2,371)

Note 2 - Revenue Recognition (D

Note 2 - Revenue Recognition (Details Textual) $ in Millions	3 Months Ended
	Sep. 30, 2018USD ($)
Contract with Customer, Liability, Revenue Recognized	$ 3.8
Contract with Customer, Liability, Total	$ 10.6

Note 2 - Revenue Recognition -

Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Revenues, net	$ 162,970	$ 144,613
UNITED STATES
Revenues, net	90,455	79,819
EMEA, excluding U.K. [Member]
Revenues, net	35,233	31,390
UNITED KINGDOM
Revenues, net	7,128	6,924
APAC, excluding Greater China [Member]
Revenues, net	11,629	11,489
CHINA
Revenues, net	13,422	10,717
Rest of World [Member]
Revenues, net	5,103	4,274
Consumables [Member]
Revenues, net	135,653	120,102
Instruments [Member]
Revenues, net	15,346	12,988
Service [Member]
Revenues, net	8,301	8,378
Product and Services [Member]
Revenues, net	159,299	141,766
Royalty [Member]
Revenues, net	$ 3,671	$ 2,847

Note 3 - Selected Balance She_3

Note 3 - Selected Balance Sheet Data (Details Textual) $ in Millions	Jun. 30, 2018USD ($)
ChemoCentryx, Inc (CCXI) [Member]
Available-for-sale Equity Securities, Amortized Cost Basis, Total	$ 18.8

Note 3 - Selected Balance She_4

Note 3 - Selected Balance Sheet Data - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018	Jun. 30, 2017
Raw materials	$ 32,082		$ 30,956
Finished goods	58,836		54,692
Inventories, net	$ 90,918	$ 85,648	$ 85,648

Note 3 - Selected Balance She_5

Note 3 - Selected Balance Sheet Data - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Property and equipment, cost	$ 294,414	$ 284,800
Accumulated depreciation and amortization	(147,903)	(139,452)
Property and equipment, net	146,511	145,348
Land [Member]
Property and equipment, cost	7,065	7,065
Building and Building Improvements [Member]
Property and equipment, cost	171,580	170,110
Machinery and Equipment [Member]
Property and equipment, cost	$ 115,769	$ 107,625

Note 3 - Selected Balance She_6

Note 3 - Selected Balance Sheet Data - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Intangible assets		$ 608,540
Accumulated amortization		(162,208)
Intangible assets, net	$ 632,686	446,332
Minimum [Member]
Intangible assets	809,107
Accumulated amortization	(176,421)
Intangible assets, net	632,686
Developed Technology Rights [Member]
Intangible assets		305,303
Developed Technology Rights [Member] | Minimum [Member]
Intangible assets	505,131
Trade Names [Member]
Intangible assets		89,608
Trade Names [Member] | Minimum [Member]
Intangible assets	89,567
Customer Relationships [Member]
Intangible assets		212,228
Customer Relationships [Member] | Minimum [Member]
Intangible assets	212,702
Patents [Member]
Intangible assets		$ 1,401
Patents [Member] | Minimum [Member]
Intangible assets	$ 1,707

Note 3 - Selected Balance She_7

Note 3 - Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2018USD ($)
Beginning balance	$ 446,332
Acquisitions	200,000
Other additions	285
Amortization expense	(14,313)
Currency translation	382
Ending balance	$ 632,686

Note 3 - Selected Balance She_8

Note 3 - Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Sep. 30, 2018USD ($)
2019 remainder	$ 45,850
2,020	60,475
2,021	60,120
2,022	58,424
2,023	56,549
Thereafter	351,268
Total	$ 632,686

Note 3 - Selected Balance She_9

Note 3 - Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2018USD ($)
Beginning balance	$ 597,890
Acquisitions (Note 4)	106,382
Currency translation	518
Ending balance	704,790
Protein Sciences [Member]
Beginning balance	347,918
Acquisitions (Note 4)	9,790
Currency translation	537
Ending balance	358,245
Diagnostics and Genomics [Member]
Beginning balance	249,972
Acquisitions (Note 4)	96,592
Currency translation	(19)
Ending balance	$ 346,545

Note 4 - Acquisitions (Details

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands	Aug. 01, 2018	Jul. 02, 2018	Sep. 30, 2018	Sep. 30, 2017
Payments to Acquire Businesses, Net of Cash Acquired, Total			$ 272,229	$ 10,634
QT Holdings Corporation [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 20,404
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 51,000	51,000
QT Holdings Corporation [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life		15 years
Exosome Diagnostics, Inc [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	$ 251,800	$ 251,825
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	325,000		$ 325,000
Exosome Diagnostics, Inc [Member] | Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	250,000
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	45,000
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 30,000
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life	15 years

Note 4 - Acquisitions - Prelimi

Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands	Aug. 01, 2018	Jul. 02, 2018	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018
Goodwill			$ 704,790		$ 597,890
Payments to Acquire Businesses, Net of Cash Acquired, Total			$ 272,229	$ 10,634
QT Holdings Corporation [Member]
Current assets, net of cash		$ 36
Equipment and other long-term assets		284
Intangible assets		20,000
Goodwill		9,790
Total assets acquired		30,110
Liabilities		765
Deferred income taxes, net		3,741
Net assets acquired		25,604
Payments to Acquire Businesses, Net of Cash Acquired, Total		20,404
Fair value of contingent consideration		5,200
Net assets acquired		25,604
Exosome Diagnostics, Inc [Member]
Current assets, net of cash		5,118
Equipment and other long-term assets		2,212
Intangible assets		180,000
Goodwill		96,592
Total assets acquired		283,922
Liabilities		2,624
Deferred income taxes, net		27,673
Net assets acquired		253,625
Payments to Acquire Businesses, Net of Cash Acquired, Total	$ 251,800	251,825
Fair value of contingent consideration		1,800
Net assets acquired		$ 253,625

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurements (Details Textual) - USD ($) $ in Millions	Sep. 30, 2018	Aug. 01, 2018	Jul. 02, 2018	Jun. 30, 2018
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	$ 7
Exosome Diagnostics, Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	325	$ 325
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	1.8
QT Holdings Corporation [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	51		$ 51
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	5.2
CCXI [Member]
Investments, Total	$ 18.8			$ 18.8

Note 5 - Fair Value Measureme_4

Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands		Sep. 30, 2018	Jun. 30, 2018
Total Assets		$ 69,047	$ 59,764
Contingent Consideration		6,800
Fair Value, Inputs, Level 1 [Member]
Total Assets		69,047	59,764
Contingent Consideration
Fair Value, Inputs, Level 2 [Member]
Total Assets
Contingent Consideration
Fair Value, Inputs, Level 3 [Member]
Total Assets
Contingent Consideration		6,800
Equity Securities [Member]
Investments, Fair Value Disclosure	[1]	52,084	54,286
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[1]	52,084	54,286
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[1]
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[1]
Certificates of Deposit [Member]
Investments, Fair Value Disclosure	[2]	16,963	5,478
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[2]	16,963	5,478
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[2]
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[2]
[1]	Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at September 30, 2018 and June 30, 2018 was $18.8 million
[2]	Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year.

Note 5 - Fair Value Measureme_5

Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Fair Value, Inputs, Level 3 [Member] $ in Millions	3 Months Ended
	Sep. 30, 2018USD ($)
Fair value at the beginning of period
Purchase price contingent consideration (Note 4)	7
Change in fair value of contingent consideration	(0.2)
Payments
Fair value at the end of period	$ 6.8

Note 6 - Debt and Other Finan_2

Note 6 - Debt and Other Financing Arrangements (Details Textual) - USD ($) $ in Thousands	Aug. 01, 2018	Sep. 30, 2018	Sep. 30, 2017
Proceeds from Issuance of Long-term Debt, Total		$ 580,000
Credit Agreement [Member]
Long-term Debt, Total		$ 561,900
Credit Agreement [Member] | Term Loan [Member]
Debt Instrument, Face Amount	$ 250,000
Proceeds from Issuance of Long-term Debt, Total	250,000
Revolving Credit Facility [Member] | Credit Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity	600,000
Line of Credit Facility, Additional Borrowing Capacity	$ 200,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.20%
Proceeds from Long-term Lines of Credit	$ 330,000

Note 7 - Accumulated Other Co_3

Note 7 - Accumulated Other Comprehensive Income (Loss) (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	$ 0	$ 0

Note 7 - Accumulated Other Co_4

Note 7 - Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Thousands		3 Months Ended
		Sep. 30, 2018	Sep. 30, 2017
Balance		$ 1,079,061
Balance		1,109,469
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Balance		24,682	$ 18,989
Cumulative effect adjustment for adoption for ASU 2018-02 (1)		2,371
Other comprehensive income (loss), net of tax before reclassifications			(7,792)
Balance			11,197
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member]
Cumulative effect adjustment for adoption of ASU 2016-01 (1)	[1]	(27,053)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance		(69,496)	(67,924)
Cumulative effect adjustment for adoption for ASU 2018-02 (1)
Other comprehensive income (loss), net of tax before reclassifications		(1,136)	6,968
Balance		(70,632)	(60,956)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member]
Cumulative effect adjustment for adoption of ASU 2016-01 (1)	[1]
AOCI Attributable to Parent [Member]
Balance		(44,814)	(48,935)
Cumulative effect adjustment for adoption for ASU 2018-02 (1)		2,371
Other comprehensive income (loss), net of tax before reclassifications		(1,136)	(824)
Balance		(70,632)	$ (49,759)
AOCI Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member]
Cumulative effect adjustment for adoption of ASU 2016-01 (1)	[1]	$ (27,053)
[1]	See Note 1 for further information related to the adoption of ASU 2016-01 and 2018-02.

Note 8 - Earnings Per Share (De

Note 8 - Earnings Per Share (Details Textual) - shares shares in Millions	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1.3	1.3

Note 8 - Earnings Per Share - S

Note 8 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Net earnings	$ 17,403	$ 15,863
Income allocated to participating securities	(16)	(10)
Income available to common shareholders	$ 17,387	$ 15,853
Basic (in shares)	37,697	37,376
Basic (in dollars per share)	$ 0.46	$ 0.42
Net Income	$ 17,403	$ 15,863
Income available to common shareholders	$ 17,387	$ 15,853
Weighted average common shares outstanding-basic (in shares)	37,697	37,376
Dilutive effect of stock options and restricted stock units (in shares)	1,116	329
Weighted average common shares outstanding-diluted (in shares)	38,813	37,705
Diluted (in dollars per share)	$ 0.45	$ 0.42

Note 9 - Share-based Compensa_2

Note 9 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	900,000	600,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 173.33	$ 114.60
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 34.30	$ 20.47
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	166,577	32,625
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 14.9	$ 0.9
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 42.7
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 146 days
Selling, General and Administrative Expenses [Member]
Allocated Share-based Compensation Expense, Total	$ 11.6	$ 3.8
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	53,903	500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 170.74	$ 122.57
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	11,279	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 177.32

Note 10 - Other Income (Expen_3

Note 10 - Other Income (Expense) - Schedule of Components of Other Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Interest expense	$ (5,239)	$ (2,243)
Interest income	102	76
Other non-operating income (expense), net	(3,040)	(897)
Total other income (expense)	$ (8,177)	$ (3,064)

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Effective Income Tax Rate Reconciliation, Percent, Total	1.00%	30.90%
Income Tax Expense (Benefit), Discrete Tax Items	$ 4.2	$ 0.4

Note 12 - Segment Information -

Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Net sales	$ 162,970	$ 144,613
Operating income	25,763	26,031
Costs recognized on sale of acquired inventory	(935)	(318)
Amortization of acquisition related intangible assets	(14,313)
Corporate general, selling, and administrative expenses	(67,051)	(58,289)
Operating Segments [Member]
Operating income	57,150	53,488
Operating Segments [Member] | Protein Sciences [Member]
Net sales	126,391	108,113
Operating income	54,614	46,209
Operating Segments [Member] | Diagnostics and Genomics [Member]
Net sales	36,747	36,589
Operating income	2,536	7,279
Intersegment Eliminations [Member]
Net sales	(168)	(89)
Segment Reconciling Items [Member]
Costs recognized on sale of acquired inventory	(935)	(318)
Amortization of acquisition related intangible assets	(14,276)	(11,379)
Acquisition related expenses	(2,631)	(9,533)
Stock-based compensation	(11,565)	(3,795)
Corporate, Non-Segment [Member]
Corporate general, selling, and administrative expenses	$ (1,980)	$ (2,432)

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) $ in Millions	Oct. 31, 2018USD ($)
Subsequent Event [Member]
Derivative, Amount of Hedged Item	$ 380